Article Sidebar

Download
Statistic
Read Counter : 18

Downloads

Download data is not yet available.

Main Article Content

Abstract

This study aims to describe the prevalence and analyze risk factors associated with the incidence of Drug-Resistant Tuberculosis (DR-TB), as well as to analyze the readiness of the implementation of the BPaL/M regimen in South Kalimantan based on patient characteristics. This study used an observational-analytical approach with a cross-sectional design. Data were obtained from the South Kalimantan Provincial Tuberculosis Information System in 2022-2023. The study sample consisted of 151 patients with DR-TB. The chi-square test was used for statistical analysis. The incidence of DR-TB in South Kalimantan in 2023 was 0.95%, with the highest incidence coming from Banjarmasin City, namely 37.36%. Drug-resistant tuberculosis (DR-TB) in South Kalimantan was most common in the elderly (>45 years) (54.30%), men (62.91%), unemployed (56.29%), and non-pregnant (98.68%). Most drug-resistant TB patients were individuals who had undergone previous treatment (63.58%), did not have comorbid DM (75.50%) and were HIV negative (98.68%). A total of 76.16% received a short-term therapy regimen and 94.70% of RO-TB patients in 2022-2023 met the criteria for receiving BPaL/M regimen therapy. The conclusion of this study is that the factors that influence the incidence of RO-TB in South Kalimantan are occupation (p 0.016), history of previous TB treatment (p 0.000) and HIV status (p 0.000), the BPaL/M regimen with a shorter duration (6 months) can be implemented in RO-TB patients in South Kalimantan by continuously improving monitoring to achieve and reduce side effects of drug events.

Keywords

Age Rifampicin Resistant TB Pregnant HIV DM Comorbid

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Author Biographies

Dita Ayulia Dwi Sandi, Universitas Lambung Mangkurat

Program Studi Farmasi, Fakultas Matematika dan Ilmu Pengetahuan Alam, Universitas Lambung Mangkurat

Ika Maulida Nurrahma, Faculty of health sciences, UPN Veteran jakarta

Dinas Kesehatan Provinsi Kalimantan Selatan, Banjarmasin

Nazhipah Isnani , Program Studi Farmasi, Fakultas Matematika dan Ilmu Pengetahuan Alam, Universitas Lambung Mangkurat

Program Studi Farmasi, Fakultas Matematika dan Ilmu Pengetahuan Alam, Universitas Lambung Mangkurat
How to Cite
Sandi, D. A. D., Nurrahma, I. M., & Isnani , N. (2025). Characteristics of Drug-Resistant TB Patients in South Kalimantan: An Ecological Study of Readiness for Implementation of the BPaL/M Regimen. Borneo Journal of Pharmascientech, 9(2). https://doi.org/10.59053/bjp.v9i2.738
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Anisah, A., Sumekar, D. W., & Budiarti, E. (2021). Hubungan Demografi dan Komorbid dengan Kejadian Tuberkulosis Resisten Obat (TB RO). Jurnal Ilmiah Kesehatan Sandi Husada, 10(2), 568–574. https://doi.org/10.35816/jiskh.v10i2.655
  2. Azwar, G. A., Indah Noviana, D., & Hendriyono, F. X. (2017). KARAKTERISTIK PENDERITA TUBERKULOSIS PARU DENGAN MULTIDRUG-RESISTANT TUBERCULOSIS (MDR-TB) DI RSUD ULIN BANJARMASIN. Berkala Kedokteran, 13(1), 23–32.
  3. Burhan, E., Karyana, M., Karuniawati, A., Kusmiati, T., Wibisono, B. H., Handayani, D., Riyanto, B. S., Gede Ketut Sajinadiyasa, I., Sinaga, B. Y. M., Djaharuddin, I., Sugiyono, R. I., Susanto, N. H., Diana, A., Kosasih, H., Lokida, D., Siswanto, Neal, A., Lau, C. Y., & Siddiqui, S. (2022). Characteristics of Drug-sensitive and Drug-resistant Tuberculosis Cases among Adults at Tuberculosis Referral Hospitals in Indonesia. American Journal of Tropical Medicine and Hygiene, 107(5), 984–991. https://doi.org/10.4269/ajtmh.22-0142
  4. Conradie, F., Bagdasaryan, T. R., Borisov, S., Howell, P., Mikiashvili, L., Ngubane, N., Samoilova, A., Skornykova, S., Tudor, E., Variava, E., Yablonskiy, P., Everitt, D., Wills, G. H., Sun, E., Olugbosi, M., Egizi, E., Li, M., Holsta, A., Timm, J., … Spigelman, M. (2022). Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis. New England Journal of Medicine, 387(9), 810–823. https://doi.org/10.1056/nejmoa2119430
  5. Dheda, K., Cox, H., Esmail, A., Wasserman, S., Chang, K. C., & Lange, C. (2018). Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB? Respirology, 23(1), 36–45. https://doi.org/10.1111/resp.13143
  6. Johnson, T. M., Rivera, C. G., Lee, G., & Zeuli, J. D. (2024). Pharmacology of emerging drugs for the treatment of multi-drug resistant tuberculosis. In Journal of Clinical Tuberculosis and Other Mycobacterial Diseases (Vol. 37). Elsevier Ltd. https://doi.org/10.1016/j.jctube.2024.100470
  7. Kemenkes RI. (2020). PETUNJUK TEKNIS PENATALAKSANAAN TUBERKULOSIS RESISTAN OBAT DI INDONESIA. Kementerian Kesehatan Republik Indonesia.
  8. Kemenkes RI. (2023). Buku Pegangan Operasional : Pengobatan Tuberkulosis Resisten Obat dengan Panduan BPaL/M. Kementerian Kesehatan Republik Indonesia.
  9. Kemenkes RI. (2024). Profil Kesehatan Indonesia Tahun 2023. Kementerian Kesehatan Republik Indonesia.
  10. Kementerian Kesehatan RI. (2022). PROFIL KESEHATAN INDONESIA 2022.
  11. Manggasa, D. D., & Suharto, D. N. (2022). Riwayat Pengobatan dan Komorbid Diabetes Mellitus Berhubungan Dengan Kejadian Tuberkulosis Resisten Obat. Poltekita : Jurnal Ilmu Kesehatan, 15(4), 403–408. https://doi.org/10.33860/jik.v15i4.659
  12. Nailius, I. S., & Anshari, D. (2022). Hubungan Karakteristik Sosial Demografi dan Literasi Kesehatan Dengan Kepatuhan Minum Obat Pada Penderita Tuberkulosis di Kota Kupang. Perilaku Dan Promosi Kesehatan: Indonesian Journal of Health Promotion and Behavior, 4(2), 43. https://doi.org/10.47034/ppk.v4i2.6332
  13. Occhineri, S., Matucci, T., Rindi, L., Tiseo, G., Falcone, M., Riccardi, N., & Besozzi, G. (2022). Pretomanid for tuberculosis treatment: an update for clinical purposes. Current Research in Pharmacology and Drug Discovery, 3, 1. https://doi.org/10.1016/j.crphar.2022.100128
  14. Pontali, E., Sotgiu, G., D’Ambrosio, L., Centis, R., & Migliori, G. B. (2016). Bedaquiline and multidrug-resistant tuberculosis: A systematic and critical analysis of the evidence. European Respiratory Journal, 47(2), 394–402. https://doi.org/10.1183/13993003.01891-2015
  15. Pusdatin, K. R. (2018). Infodatin : Tuberkulosis. www.who.int/gho/mortality_burden_disease/cause_death/top10/en/
  16. Putra, O. N., & Purnamasari, T. (2024). BPaL/BpaLM regimen: A bright future for drug-resistant tuberculosis. Asian Pacific Journal of Tropical Medicine, 17(8), 335–337. https://doi.org/10.4103/apjtm.apjtm_244_24
  17. Redfield, R. R., Bunnell, R., Greenspan, A., Kent, C. K., Damon, G., Dunworth, S., Hood, T. M., Leahy, M. A., Martinroe, J. C., Spriggs, S. R., Yang, T., Doan, Q. M., King, P. H., Starr, T. M., Yang, M., Jones, T. F., Michelle Bonds, C. E., Matthew Boulton, M. L., Carolyn Brooks, M., … Bobb Swanson, M. (2020). Morbidity and Mortality Weekly Report Centers for Disease Control and Prevention MMWR Editorial and Production Staff (Weekly) MMWR Editorial Board. In Rep (Vol. 69).
  18. Salsabila, L. Z., Susanti, R., Kuswida Bhakti, W., Prof, J., & Nawawi, H. (2022). ANALISIS FAKTOR TINGKAT KEPATUHAN MINUM OBAT ANTI TUBERKULOSIS PADA PASIEN TB PARU RAWAT JALAN DI PUSKESMAS PERUMNAS 1 KOTA PONTIANAK TAHUN 2021. Jurnal Mahasiswa Farmasi Fakultas Kedokteran UNTAN, 6(1).
  19. Silva, D. R., Fernandes, F. F., Ferreira, J. C., Bernando, W., Dalcolmo, M. M. P., Johansen, F. D. C., & Mello, F. C. de Q. (2025). Bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) for multidrug- or rifampin-resistant tuberculosis: a systematic review. Jornal Brasileiro de Pneumologia : Publicacao Oficial Da Sociedade Brasileira de Pneumologia e Tisilogia, 50(6), e20240295. https://doi.org/10.36416/1806-3756/e20240295
  20. Soeroto, A. Y., Pratiwi, C., Santoso, P., & Lestari, B. W. (2021). Factors affecting outcome of longer regimen multidrug-resistant tuberculosis treatment in West Java Indonesia: A retrospective cohort study. PLoS ONE, 16(2 February). https://doi.org/10.1371/journal.pone.0246284
  21. Sutrisna, M., & Elsi Rahmadani. (2022). Hubungan Usia dan Jenis Kelamin dengan TB MDR. Sehat Rakyat: Jurnal Kesehatan Masyarakat, 1(4), 370–376. https://doi.org/10.54259/sehatrakyat.v1i4.1168
  22. Vanderah, T. W. (2024). Katzung’s Basic & Clinical Pharmacology, 16th Edition. In Katzung’s Basic & Clinical Pharmacology, 16th Edition. McGraw-Hill. accessmedicine.mhmedical.com/content.aspx?aid=1204121896
  23. WHO. (2020). GLOBAL TUBERCULOSIS REPORT 2020. World Health Organization.
  24. WHO. (2025). WHO consolidated guidelines on tuberculosis. Module 4: Treatment and care. World Health Organization.
  25. Wu, L., Cai, X., & Jiang, X. (2024). Risk factors for multidrug-resistant tuberculosis: a predictive model study. Frontiers in Medicine, 11. https://doi.org/10.3389/fmed.2024.1410690